ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
23.380,70
1,08%
S&P 500
5.614,66
-1,07%
Dow Jones
41.581,31
-0,62%
Euro vs US Dollar
1,09455
0,25%
Bitcoin
82.061,48
-2,38%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Citius Pharmaceuticals Inc (CTXR)

  7. Citius Pharmaceuticals Inc (CTXR) News

CTXR

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CTXR
DatumZeitQuelleÜberschriftSymbolFirma
10/03/202521h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202522h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202522h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202522h30PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
06/02/202515h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
06/02/202514h55PR Newswire (US)Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid ServicesNASDAQ:CTXRCitius Pharmaceuticals Inc
27/01/202522h13Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:CTXRCitius Pharmaceuticals Inc
27/01/202522h10Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CTXRCitius Pharmaceuticals Inc
27/01/202522h07Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CTXRCitius Pharmaceuticals Inc
27/01/202522h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CTXRCitius Pharmaceuticals Inc
16/01/202522h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CTXRCitius Pharmaceuticals Inc
08/01/202522h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
08/01/202515h00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CTXRCitius Pharmaceuticals Inc
08/01/202514h00PR Newswire (US)Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:CTXRCitius Pharmaceuticals Inc
07/01/202515h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
07/01/202514h08PR Newswire (US)Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025NASDAQ:CTXRCitius Pharmaceuticals Inc
06/01/202513h50PR Newswire (US)Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic AlternativesNASDAQ:CTXRCitius Pharmaceuticals Inc
27/12/202423h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
27/12/202423h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTXRCitius Pharmaceuticals Inc
27/12/202423h00PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
20/12/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
26/11/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
25/11/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
25/11/202414h03PR Newswire (US)Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNASDAQ:CTXRCitius Pharmaceuticals Inc
22/11/202415h00PR Newswire (US)Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock SplitNASDAQ:CTXRCitius Pharmaceuticals Inc
18/11/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
18/11/202422h05PR Newswire (US)Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
18/11/202414h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CTXRCitius Pharmaceuticals Inc
15/11/202419h30PR Newswire (US)Citius Pharmaceuticals Announces $3 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
13/11/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CTXR

Kürzlich von Ihnen besucht

UNSW
LEADETH
Lead Token
EU
DPT
ST Dupont
BIT
QFID
B Antonveneta
LSE
KQ73
Morg.st.b.v 25
LSE
PV14
Ksa Sukuk.30 U
COIN
BGTTETH
Baguette Token
LSE
RA36
Mar Fin 24
BIT
CLEU
Lyxor Msci Europe Esg Cl...
COIN
BGTTUSD
Baguette Token
LSE
QL07
Morg.st.b.v 25
LSE
11IN
Investec Bnk 23
COIN
TUDAUSD
TudaToken
COIN
ASSYETH
ASSY Index
LSE
BCPT
Balanced Commercial Prop...
NYSE
BKH
Black Hills
COIN
SPLCUST
SupplyCon
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten